CCCarlos Cuevas

Carlos Cuevas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carlos Cuevas has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Abstract A92: Murine clinical trials program

    by J. Scott Brockenbrough, Libing Feng, Ingunn M. Stromnes, Kathleen E. DelGiorno, Martin C. Whittle, Carlos Cuevas, Ashley M. Dotson, Joseph S. Ryan, Shelley M. Thorsen, Sunil R. Hingorani

    Enormous advances in the biomedical sciences have raised tenable hope of a new era of personalized medicine. Significant hurdles to realizing this goal include the inordinately high and evolving degree of genetic and biologic diversity in carcinomas, even within categories of defined organ and cell-type. In addition, the tissue culture and xenograft preclinical model systems that have been instrumental in elucidating fundamental principles of cancer biology do not recapitulate the essential geometry or tissue and stromal interactions encountered in the native disease. As a result, the ability to kill cancer cells in these contexts has had limited impact on treating the diseases in patients. Genetically engineered mouse models of pancreas cancer appear to encompass the biological diversity and complexity seen in patients. In addition to revealing important aspects of disease pathobiology, these model systems form the basis of a preclinical platform, the Murine Clinical Trials Program (MCTP), designed to accelerate the development and evaluation of early detection, chemoprevention and therapeutic strategies most likely to impact patients in the clinic. By screening these strategies in highly faithful animal surrogates for the human disease, we hope to rapidly identify and translate the most effective approaches to the clinic, while concomitantly defining the appropriate disease subtype-specific context in which to employ each application. Attempting to accomplish these aims by performing initial validation and optimization experiments directly in patients can slow progress by many years, if not preclude it altogether. Treatment strategies are advanced through the MCTP in a systematic manner with defined endpoints and criteria (“Go/No-Go”) for each step. If these criteria are met in phase A (Pilot Study), they advance to Phase B (Full Survival Study). Strict enrollment criteria ensure the presence of invasive PDA (with or without metastatic disease) while also allowing sufficient time on investigational therapy to reveal potential resistance mechanisms, unanticipated secondary or off-target effects and delayed toxicities. Each of these aspects is described in detail in our presentation. Each new investigational agent in both the pilot and survival studies is analyzed in three arms: 1) agent alone; 2) agent + standard cytotoxic agent(s); 3) agent + cytotoxics + anti-stromal agent. In our standard approach, pilot studies enroll n=4-5 animals per agent. A 2-5 cm mass measurable by high-resolution ultrasound is required for enrollment. The standard 3 weeks ‘on’/1 week ‘off’ treatment regimen used routinely in patients is recapitulated in mice, together with a dose and route designed to be as similar as possible to that anticipated for human patients. Primary endpoints for pilot studies (1-2 cycles of treatment) include objective response and cellular effects including tumor cell apoptosis and proliferation, immune cell responses, changes in content and character of ECM components, vessel density and cross-sectional diameter, and so on. Results from pilot studies are used to determine whether a full survival study is warranted. Examples of recent MCTP pilot and survival studies will be presented. Citation Format: J. Scott Brockenbrough, Libing Feng, Ingunn M. Stromnes, Kathleen E. DelGiorno, Martin C. Whittle, Carlos Cuevas, Ashley M. Dotson, Joseph S. Ryan, Shelley M. Thorsen, Sunil R. Hingorani. Murine clinical trials program. [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Innovations in Research and Treatment; May 18-21, 2014; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2015;75(13 Suppl):Abstract nr A92.

  • Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity

    by Ingunn M Stromnes, J Scott Brockenbrough, Kamel Izeradjene, Markus A Carlson, Carlos Cuevas, Randi M Simmons, Philip D Greenberg, Sunil R Hingorani

    Background Pancreatic ductal adenocarcinoma (PDA) is characterised by a robust desmoplasia, including the notable accumulation of immunosuppressive cells that shield neoplastic cells from immune detection. Immune evasion may be further enhanced if the malignant cells fail to express high levels of antigens that are sufficiently immunogenic to engender an effector T cell response. Objective To investigate the predominant subsets of immunosuppressive cancer-conditioned myeloid cells that chronicle and shape the progression of pancreas cancer. We show that selective depletion of one subset of myeloid-derived suppressor cells (MDSC) in an autochthonous, genetically engineered mouse model (GEMM) of PDA unmasks the ability of the adaptive immune response to engage and target tumour epithelial cells. Methods A combination of in vivo and in vitro studies were performed employing a GEMM that faithfully recapitulates the cardinal features of human PDA. The predominant cancer-conditioned myeloid cell subpopulation was specifically targeted in vivo and the biological outcomes determined. Results PDA orchestrates the induction of distinct subsets of cancer-associated myeloid cells through the production of factors known to influence myelopoiesis. These immature myeloid cells inhibit the proliferation and induce apoptosis of activated T cells. Targeted depletion of granulocytic MDSC (Gr-MDSC) in autochthonous PDA increases the intratumoral accumulation of activated CD8 T cells and apoptosis of tumour epithelial cells and also remodels the tumour stroma. Conclusions Neoplastic ductal cells of the pancreas induce distinct myeloid cell subsets that promote tumour cell survival and accumulation. Targeted depletion of a single myeloid subset, the Gr-MDSC, can unmask an endogenous T cell response, disclosing an unexpected latent immunity and invoking targeting of Gr-MDSC as a potential strategy to exploit for treating this highly lethal disease.


  • Imaging patterns of hepatic steatosis on multidetector CT: Pearls and pitfalls

    by K.K. Kani, M. Moshiri, C. Cuevas, J.H. Lee, L.M. Mitsumori, O. Kolokythas


  • Top Cited Papers

    Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

    by Paolo P. Provenzano, Carlos Cuevas, Amy E. Chang, Vikas K. Goel, Daniel D. Von Hoff, Sunil R. Hingorani


  • Top Cited Papers

    Imaging of Uncommon Retroperitoneal Masses

    by Prabhakar Rajiah, Rakesh Sinha, Carlos Cuevas, Theodore J. Dubinsky, William H. Bush, Orpheus Kolokythas

    Retroperitoneal masses not arising from major solid organs are uncommon. Although there is no simple method of classifying retroperitoneal masses, a reasonable approach is to consider the masses as predominantly solid or cystic and to subdivide these into neoplastic and nonneoplastic masses. Because the treatment options vary, it is useful to be able to differentiate these masses by using imaging criteria. Although the differential diagnosis of retroperitoneal masses can be narrowed down to a certain extent on the basis of imaging characteristics, patterns of involvement, and demographics, there is still a considerable overlap of imaging findings for these masses, and histologic examination is often required for definitive diagnosis. Computed tomography (CT) and magnetic resonance (MR) imaging play an important role in characterization and in the assessment of the extent of the disease and involvement of adjacent and distant structures. Familiarity with the CT and MR imaging features of various retroperitoneal masses will facilitate accurate diagnosis and staging for aggressive lesions.


  • Chronic Pelvic Pain

    by Theodore Dubinsky, Manjiri Dighe, Carlos Cuevas

  • Medical imaging in the diagnosis and management of cancer pain

    by Carlos Cuevas, Dean Shibata

    LLC Within the past few decades medical imaging has evolved very rapidly, now becoming an indispensable tool for the diagnosis, treatment, and follow-up of patients with cancer-related pain. Multiple imaging modalities are available for the assessment of cancer patients, each one with different advantages and limitations that are important to consider at the time we order a diagnostic study or plan an image-guided procedure. This article reviews the role that various imaging modalities play in the management of cancer pain and provides an overview of the latest technological advances.


  • Sonography in first trimester bleeding

    by Manjiri Dighe, Carlos Cuevas, Mariam Moshiri, Theodore Dubinsky, Vikram S. Dogra

    Vaginal bleeding is the most common cause of presentation to the emergency department in the first trimester. Approximately half of patients with first trimester vaginal bleeding will lose the pregnancy. Clinical assessment is difficult, and sonography is necessary to determine if a normal fetus is present and alive and to exclude other causes of bleeding (eg, ectopic or molar pregnancy). Diagnosis of a normal intrauterine pregnancy not only helps the physician in terms of management but also gives psychologic relief to the patient. Improved ultrasound technology and high‐frequency endovaginal transducers have enabled early diagnosis of abnormal and ectopic pregnancies, decreasing maternal morbidity and mortality. The main differential considerations of first trimester bleeding are spontaneous abortion, ectopic pregnancy, or gestational trophoblastic disease. This article reviews the causes of first trimester bleeding and the sonographic findings, including normal features of first trimester pregnancy. © 2008 Wiley Periodicals, Inc. J Clin Ultrasound, 2008.